الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 128 |  |  |
| | | from | 128 | | |
Abstract
Breast cancer is the most common cancer in women worldwide and br is one of the most common cancers overall about 23% of all cancers. br Breast cancer is the most common cause of cancer death in women. In br Egypt breast carcinoma constitutes 33% of all female cancers in Egyptian br national cancer institute. br Triple negative breast cancer (TNBC) accounts for approximately br 10-15% of breast cancer cases. TNBC is characterized by the absence of br receptors to estrogen, progesterone and no immunohistochemical br expression of HER-2 growth factor, with significant diversity within the br subtype. Generally TNBC occurs in younger women and is marked by br high rates of relapse, visceral and CNS metastases, and early death. br TNBC does not benefit -#102;-#114;-#111;-#109; established targeted drugs with endocrine br therapy or trastuzumab. The poor prognosis coupled with a lack of br targeted use of therapies is reflected in the high mortality. br The great interest in triple-negative breast cancers is not surprising, br because these cancers benefit neither -#102;-#114;-#111;-#109; hormonal therapies nor -#102;-#114;-#111;-#109; br treatments targeted against HER2 receptors. The only systemic therapy br currently available is chemotherapy, and prognosis remains poor. There is br currently no standard targeted therapy for women with TN breast cancer br (TNBC), Cytotoxic chemotherapy is the mainstay of systemic treatment. br Capecitabine is an effective agent even in anthracycline/taxanepretreated br MBC. Yet little is known about the efficacy of Capecitabine as br adjuvant treatment of early breast cancer. Capecitabine is also being br - 115 - br evaluated as a maintenance therapy after standard adjuvant therapy in two br ongoing phase III studies CIBOMA and SYSCBS-001. br This prospective phase II study aims to assess the tolerability and br efficacy of metronomic chemotherapy as extended adjuvant in women br with triple negative breast cancer TNBC. Extended adjuvant metronomic br Capecitabine was well tolerated with no sever or life threatening adverse br effects which is consistent with the safety profile published by CIBOMA br trial. The estimated median follow- up duration is 24.0 months (95% CI, br 21.76-26.24). The estimated mean DFS is 33.65 months (95% CI, 31.83- br 36.47), while the median DFS is not reached. These results are immature br larger sample as well as longer follow-up period are recommended. br Conclusion br Extended adjuvant metronomic Capecitabine is well tolerated br with good patients’ compliance and may be beneficial in women with br TNBC who don’t benefit -#102;-#114;-#111;-#109; hormonal therapy and Trastuzumab.